CD123 Targeted Therapies
1 drugsAbout CD123
CD123, or IL-3Rα, is a receptor found on hematopoietic stem cells and immune cells. It binds interleukin-3 (IL-3), a cytokine that regulates cell growth, survival, and differentiation.
CD123 is a therapeutic target due to its overexpression in hematological malignancies, making it a potential target to selectively eliminate cancerous cells. Currently, there is no genetic evidence directly linking CD123 to specific diseases.
CD123 is targeted by one FDA-approved biologic drug, ELZONRIS. STEMLINE THERAPEUTICS INC is the sole company in this space.
Top CD123 Drugs
STEMLINE THERAPEUTICS INC is the only company with an approved drug.
High market concentration suggests high barriers to entry or limited commercial opportunity.
CD123 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD123, using biologic (other) modality.
The lack of small molecule or antibody drugs represents a whitespace opportunity.
CD123 Clinical Trials 18 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD123. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 2 | 4 | 6 | 33% |
| Phase 2 | 6 | 0 | 2 | 4 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CD123 Drug Approval Timeline (2018 - 2018)
The first and only drug was approved in 2018.
Recent entry suggests potential for growth, but lack of follow-on approvals indicates possible target saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD123. A trial counts if an approved drug acting on CD123 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.